2025 biotech conferences and events - Labiotech.eu
January 2025:. 22-23 January 2025: Paris, France – Pharmapack 28-30 January 2025: Frankfurt, Germany – mRNA-based Therapeutics Summit 29-30 January 2025: London, UK – Festival of Genomics and Biodata; February 2025: 4 February 2025: Zurich, Switzerland – Zurich Life Science Day 2025; 6-8 February 2025: Strasbourg, France – 7th European CAR T-cell Meeting
What trends will shape the biotech industry in 2024?
Jan 25, 2024 · AI reshaping biotech: A key trend for 2024. AI has completely shifted the paradigm in the biotech industry. The past year has seen a gold rush in AI applications for the biopharma sector, for drug and protein discovery, or even treatment repurposing.
Nine biotech companies to watch in 2024
Dec 19, 2023 · 2024 is shaping up to be an exciting year for the industry. Discover nine biotech companies to keep an eye on in 2024.
Seven diseases CRISPR technology could cure - Labiotech.eu
Apr 4, 2024 · CRISPR technology offers the promise to cure human genetic diseases with gene editing. This promise became a reality when the world’s first CRISPR therapy was approved by regulators to treat patients with sickle cell disease and beta-thalassemia last year.. American biopharma Vertex Pharmaceuticals’ CASGEVY works by turning on the BCL11A gene, which codes for fetal hemoglobin.
Needle-free diabetes care: 7 devices that painlessly monitor blood …
Oct 7, 2022 · Will the daily routine of finger pricking to monitor blood sugar levels finally come to an end for the millions living with diabetes? Diabetes affects over 537 million adults worldwide. People with diabetes have to test their blood sugar levels several times a day, usually by pricking their finger with a lancet. This can be uncomfortable …
Promising cure for COPD: is a breakthrough within reach?
Oct 9, 2024 · FDA approves two new COPD treatments in 2024 Verona Pharma’s Ohtuvayre. In June 2024, the FDA approved the first inhaled product with a novel mechanism of action available for the maintenance treatment of COPD in more than 20 years. The product, called Ohtuvayre (ensifentrine), was developed by Verona Pharma – a London-based company established 19 years ago to unlock the potential of ...
Recent biotech fundings: The 2024 tracker
Discover the latest in biotech funding on our dedicated page. We meticulously curate and categorize significant fundraising events to keep you informed about the cutting-edge trends and investments driving the industry forward.
Labiotech.eu - Europe's leading Biotech News Website
3 days ago · Labiotech.eu covers the global biotech industry, read by 150,000+ monthly visitors. Hope you'll enjoy our Biotech News!
Recent biotech deals: The 2024 tracker
January 2024: AbbVie and Umoja Biopharma, both based in the United States, are partnering to develop novel in-situ CAR-T cell therapies. Umoja is eligible to receive up to $1.44 billion for option exercise fees, development, and regulatory milestones.
The future of diabetes treatment: Is a cure possible? - Labiotech.eu
Jan 15, 2024 · The company announced in 2023 the completion of enrollment in the phase II IMPACT trial for IMCY-0098, their most advanced imotope designed to halt the progression of diabetes by stopping the body’s immune system from attacking beta-cells. An imotope is a synthetic peptide containing a T-cell epitope and a thioredox motif. To put it more simply, imotopes target the autoimmune pathway without ...